PTC Therapeutics, Inc. Deferred Tax Assets, Deferred Income
PTC Therapeutics, Inc. (PTCT) had Deferred Tax Assets, Deferred Income of $448.07 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2026-02-19
- 2025-12-31: Deferred Tax Assets, Deferred Income $448.07M.
- 2024-12-31: Deferred Tax Assets, Deferred Income $394.13M.
- 2023-12-31: Deferred Tax Assets, Deferred Income $190.66M.
- 2022-12-31: Deferred Tax Assets, Deferred Income $185.59M.
| Period end | Deferred Tax Assets, Deferred Income | Deferred Tax Assets, Deferred Income as first filed |
|---|---|---|
| 2025-12-31 | $448.07M 10-K · filed 2026-02-19 | |
| 2024-12-31 | $394.13M 10-K · filed 2026-02-19 | |
| 2023-12-31 | $190.66M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $185.59M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $148.50M 10-K · filed 2023-02-21 | |
| 2020-12-31 | $161.20M 10-K · filed 2022-02-22 | |
| 2014-12-31 | $699.00K 10-K · filed 2016-02-29 | |
| 2013-12-31 | $350.00K 10-K · filed 2015-03-02 | $350.45K 10-K · filed 2014-03-06 |
| 2012-12-31 | $6.96M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |